Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity

European Journal of Immunology

Volumn 36, Issue 10, 2006, Pages 2768-2780

  Alexopoulou, Lena ^a,d   Kranidioti, Ksanthi ^a   Xanthoulea, Sofia ^a,e   Denis, Maria ^a   Kotanidou, Anastasia ^b   Douni, Eleni ^a   Blackshear, Perry J ^c   Kontoyiannis, Dimitris L ^a   Kollias, George ^a  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Animal models; Cell surface molecules; Cytokines; Lymphoid organs; Neuroimmunology

Indexed keywords

GALACTOSAMINE; LIPOPOLYSACCHARIDE; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; BACTERIAL INFECTION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOST RESISTANCE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; MOUSE; MOUSE MUTANT; MUTAGENESIS; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; T LYMPHOCYTE; THYMOCYTE; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNITY; BACTERIAL INFECTIONS; BLOTTING, NORTHERN; CELL MEMBRANE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPH NODES; MICE; MICE, TRANSGENIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750269857     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200635921     Document Type: Article

References (70)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N. and Williamson, B., An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 1975. 72: 3666-3670.
2. Beutler, B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y. C., Mathison, J., Ulevitch, R. and Cerami, A., Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985. 316: 552-554.
3. Vassalli, P., The pathophysiology of rumor necrosis factors. Annu. Rev. Immunol. 1992. 10: 411-452.
4. Kollias, G., Douni, E., Kassiotis, G. and Kontoyiannis, D., On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. 1999. 169: 175-194.
5. Kriegler, M., Perez, C., DeFay, K., Albert, I. and Lu, S. D., A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988. 53: 45-53.
6. Vandenabeele, P., Declercq, W., Beyaert, R. and Fiers, W., Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995. 5: 392-399.
7. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S. et al., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995. 83: 793-802.
8. Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V. and Boldin, M. P., Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999. 17: 331-367.
9. Tartaglia, L. A. and Goeddel, D. V., Two TNF receptors. Immunol. Today 1992. 13: 151-153.
10. Hooper, N. M., Karran, E. H. and Turner, A. J., Membrane protein secretases. Biochem. J. 1997. 321: 265-279.
11. Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J. et al., A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997. 385: 729-733.
12. Moss, M. L., Jin, S. L., Becherer, J. D., Bickett, D. M., Burkhart, W., Chen, W. J., Hassler, D. et al., Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J. Neuroimmunol. 1997. 72: 127-129.
13. Alexopoulou, L., Pasparakis, M. and Kollias, G., A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur. J. Immunol. 1997. 27: 2588-2592.
14. Kusters, S., Tiegs, G., Alexopoulou, L., Pasparakis, M., Douni, E., Kunstle, G., Bluethmann, H. et al., In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur. J. Immunol. 1997. 27: 2870-2875.
15. Akassoglou, K., Probert, L., Kontogeorgos, G. and Kollias, G., Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J. Immunol. 1997. 158: 438-445.
16. Alexopoulou, L., Pasparakis, M. and Kollias, G., Complementation of lymphotoxin alpha knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function, J. Exp. Med. 1998. 188: 745-754.
17. Ruuls, S. R., Hoek, R. M., Ngo, V. N., McNeil, T., Lucian, L. A., Janatpour, M. J., Korner, H. et al., Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001. 15: 533-543.
18. Feldmann, M. and Maini, R. N., Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 2001. 19: 163-196.
19. Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N. and Braun, M. M., Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001. 345: 1098-1104.
20. Lee, J. H., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P. et al., Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002. 46: 2565-2570.
21. Slifman, N. R., Gershon, S. K., Lee, J. H., Edwards, E. T. and Braun, M. M., Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003. 48: 319-324.
22. Tai, T. L., O'Rourke, K. P., McWeeney, M., Burke, C. M., Sheehan, K. and Barry, M., Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 2002. 41: 951-952.
23. Shakoor, N., Michalska, M., Harris, C. A. and Block, J. A., Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002. 359: 579-580.
24. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999. 53: 457-465.
25. van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M., Woody, J. N. et al., Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996. 47: 1531-1534.
26. Cush, J. J., Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin. Exp. Rheumatol. 2004. 22: S141-147.
27. Brown, S. L., Greene, M. H., Gershon, S. K., Edwards, E. T. and Braun, M. M., Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002. 46: 3151-3158.
28. Smith, K. J. and Skelton, H. G., Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgGl-Fc fusion complex therapy. J. Am. Acad. Dermatol. 2001. 45: 953-956.
29. Sfikakis, P. P. and Kollias, G., Tumor necrosis factor biology in experimental and clinical arthritis. Curr. Opin. Rheumatol. 2003. 15: 380-386.
30. Kollias, G. and Kontoyiannis, D., Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 2002. 13: 315-321.
31. Pasparakis, M., Alexopoulou, L., Episkopou, V. and Kollias, G., Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 1996. 184: 1397-1411.
32. Nygard, N. R., McCarthy, D. M., Schiffenbauer, J. and Schwartz, B. D., Mixed haplotypes and autoimmunity. Immunol. Today 1993. 14: 53-56.
33. Kontoyiannis, D. and Kollias, G., Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur. J. Immunol. 2000. 30: 2038-2047.
34. Kassiotis, G. and Kollias, G., Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 2001. 193: 427-434.
35. Fremond, C., Dambusza, L, Allie, N., Jacobs, M., Grivennikov, S., Quesniaux, V. F. and Ryffel, B., Membrane TNF confers protection to acute mycobacterial infection. Respir. Res. 2005. 6: 136.
36. Decoster, E., Vanhaesebroeck, B., Vandenabeele, P., Grooten, J. and Fiers, W., Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J. Biol. Chem. 1995. 270: 18473-18478.
37. Lehmann, V., Freudenberg, M. A. and Galanos, C., Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and d-galactosa-mine-treated mice. J. Exp. Med. 1987. 165: 657-663.
38. Pfeffer, K., Matsuyama, T., Kundig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K. et al., Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993. 73: 457-467.
39. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A. et al., Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993. 364: 798-802.
40. Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H. et al., Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994. 370: 555-557.
41. Grell, M., Becke, F. M., Wajant, H., Mannel, D. N. and Scheurich, P., TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 1998. 28: 257-263.
42. Pasparakis, M., Alexopoulou, L., Grell, M., Pfizenmaier, K., Bluethmann, H. and Kollias, G., Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc. Natl. Acad. Sci. USA 1997. 94: 6319-6323.
43. Peschon, J. J., Torrance, D. S., Stocking, K. L., Glaccum, M. B., Otten, C., Willis, C. R., Charrier, K. et al., TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 1998. 160: 943-952.
44. Saunders, B. M., Tran, S., Ruuls, S., Sedgwick, J. D., Briscoe, H. and Britton, W. J., Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol. 2005. 174: 4852-4859.
45. Taylor, G. A., Carballo, E., Lee, D. M., Lai, W. S., Thompson, M, J., Patel, D. D., Schenkman, D. I. et al., A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996. 4: 445-454.
46. Carballo, E. and Blackshear, P. J., Roles of tumor necrosis factor-alpha receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome. Blood 2001. 98: 2389-2395.
47. Carballo, E., Gilkeson, G. S. and Blackshear, P. J., Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/ macrophage progenitors may be responsible for TNFalpha overproduction. J. Clin. Invest. 1997. 100: 986-995.
48. Korner, H., Riminton, D. S., Strickland, D. H., Lemckert, F. A., Pollard, J. D. and Sedgwick, J. D., Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med. 1997. 186: 1585-1590.
49. Kassiotis, G., Pasparakis, M., Kollias, G. and Probert, L., TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur. J. Immunol, 1999. 29: 774-780.
50. Eugster, H. P., Frei, K., Bachmann, R., Bluethmann, H., Lassmann, H. and Fontana, A., Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur. J. Immunol. 1999. 29: 626-632.
51. Kassiotis, G., Kranidioti, K. and Kollias, G., Defective CD4T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness. J. Neuroimmunol. 2001. 119: 239-247.
52. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D. and Kollias, G., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991. 10: 4025-4031.
53. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F. and Kollias, G., Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999. 10: 387-398.
54. Dinarello, C. A., Anti-cytokine therapeutics and infections. Vaccine 2003. 21 Suppl 2: S24-34.
55. Decoster, E., Vanhaesebroeck, B., Boone, E., Plaisance, S., De Vos, K., Haegeman, G., Grooten, J. and Fiers, W., Induction of unresponsiveness to tumor necrosis factor (TNF) after autocrine TNF expression requires TNF membrane retention. J. Biol. Chem. 1998. 273: 3271-3277.
56. Fu, Y. X. and Chaplin, D. D., Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 1999. 17: 399-433.
57. Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schreiber, R. et al., Tumor necrosis factor-alpha is required in the protective immune response. Immunity 1995. 2: 561-572.
58. Torres, D., Janot, L., Quesniaux, V. F., Grivennikov, S. L, Maillet, L, Sedgwick, J. D., Ryffel, B. and Erard, F., Membrane tumor necrosis factor confers partial protection to listeria infection. Am. J. Pathol. 2005. 167: 1677-1687.
59. Zhang, Y., Xu, J., Levin, J., Hegen, M., Li, G., Robertshaw, H., Brennan, F. et al., Identification and characterization of 4- 4-(2-butynyloxy)phenyl]-sulfonyl]- N-hydroxy-2,2-dimethyl-(3S)thiomorpho linecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J. Pharmacol. Exp. Ther. 2004. 309: 348-355.
60. Murray, R. Z., Kay, J. G., Sangermani, D. G. and Stow, J. L., A role for the phagosome in cytokine secretion. Science 2005. 310: 1492-1495.
61. Encinas, J. A., Lees, M. B., Sobel, R. A., Symonowicz, C., Greer, J. M., Shoviin, C. L., Weiner, H. L. et al., Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. J. Immunol. 1996. 157. 2186-2192.
62. Frei, K., Eugster, H. P., Bopst, M., Constantinescu, C. S., Lavi, E. and Fontana, A., Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 1997. 185: 2177-2182.
63. Probert, L., Akassoglou, K., Pasparakis, M., Kontogeorgos, G. and Kollias, G., Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA 1995. 92: 11294-11298.
64. Gu, H., Marth, J. D., Orban, P. C., Mossmann, H. and Rajewsky, K., Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 1994. 265: 103-106.
65. Tybulewicz, V. L., Crawford, C. E., Jackson, P. K., Bronson, R. T. and Mulligan, R. C., Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991. 65: 1153-1163.
66. Robertson, E., Bradley, A., Kuehn, M. and Evans, M., Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature 1986. 323: 445-448.
67. Pasparakis, M. and Kollias, G., Production of cytokine transgenic and knockout mice. In Balkwill, F. R. (Ed.) Cytokines: A Practical Approach. Oxford University Press, Oxford 1995, pp 297-324.
68. Araki, K., Araki, M., Miyazaki, J. and Vassalli, P., Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase. Proc. Natl. Acad. Sci. USA 1995. 92: 160-164.
69. Gu, H., Zou, Y. R. and Rajewsky, K., Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 1993. 73: 1155-1164.
70. Cossart, P., Vicente, M. F., Mengaud, J., Baquero, F., Perez-Diaz, J. C. and Berche, P., Listeriolysin O is essential for virulence of Listeria monocytogenes: direct evidence obtained by gene complementation. Infect. Immun. 1989. 57: 3629-3636.